Russia's Pharmstandard receives LSE award
This article was originally published in Scrip
Pharmstandard, the largest pharmaceutical manufacturer in Russia, has received the best newcomer award from the London Stock Exchange, where the company's global depositary receipts were listed in May 2007. Augment Investments, a firm managing the stakes of Pharmstandard's main shareholders, raised $880 million in an initial public offering at that time.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.